Mefenamate
Active ingredient
Sold as PONSTAN · MEFENAMIC · MEFENAMIC ACID
- Drug class
- -
- Availability
- See label
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 24
Overview
Mefenamate is an active pharmaceutical ingredient. The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 22 | May 22, 2026 |
| CA Canada | Health Canada | 2 | March 22, 2025 |
GBUnited Kingdom· MHRA
22 products
Uses
Mefenamic acid is a non-steroidal anti-inflammatory agent with analgesic properties, and a demonstrable antipyretic effect. It has been shown to inhibit prostaglandin activity. Indications 1. As an anti-inflammatory analgesic for the symptomatic relief of rheumatoid arthritis (including Still’s Disease), osteoarthritis, and pain including muscular, traumatic and dental pain, headaches of most aetiology, post-operative and post-partum pain; pyrexia in children.
2. Primary dysmenorrhoea. 3. Menorrhagia due to dysfunctional causes and presence of an IUD when other pelvic pathology has been ruled out.
How to take
CACanada· Health Canada
2 products
Uses
Adult (>18 years old) MEFENAMIC (mefenamic acid) is indicated for the relief of pain of moderate severity in conditions such as: • muscular aches and pains • primary dysmenorrhea • headache • dental pain For patients with an increased risk of developing CV and/or GI adverse events, other management strategies that do NOT include the use of NSAIDs should be considered first (see
How to take
Drug interactions
Known interactions involving Mefenamate. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 358. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL177360004 · revised July 11, 2025
- [2]Health Canada (DPD) · 02229452 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.